---
title: "Study questions pairing monoclonal L9LS with R21 vaccine in infants against malaria"
id: "stat-news-0-study-raises-doubts-about-combining-vaccine-monoclonal-antibody-to-protect"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-study-raises-doubts-about-combining-vaccine-monoclonal-antibody-to-protect"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/11/19/malaria-monoclonal-antibody-l9ls-vaccine-r21-infant-study-mali/?utm_campaign=rss"
published_at: "2026-11-19T22:20:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Study questions pairing monoclonal L9LS with R21 vaccine in infants against malaria
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-study-raises-doubts-about-combining-vaccine-monoclonal-antibody-to-protect
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/11/19/malaria-monoclonal-antibody-l9ls-vaccine-r21-infant-study-mali/?utm_campaign=rss)
- **Published At:** 2026-11-19T22:20:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators tested the monoclonal antibody **L9LS** in infants aged 1–12 months in Mali and compared it with placebo over a six-month malaria transmission season. - The monoclonal provided about 78% protection versus placebo during that six-month window, consistent with prior data in older children and adults, the study team reported. - Study participants also received the **R21** malaria vaccine after receiving L9LS or placebo; blood tests measured antibody responses to vaccine antigens. - Data indicated a 20%–30% reduction in vaccine-elicited antibody levels among infants who had received L9LS, according to an abstract presented at the American Society of Tropical Medicine and Hygiene meeting. - Researchers propose the mechanism: both L9LS and the vaccines target the circumsporozoite protein (**CSP**), and circulating monoclonal antibody may bind vaccine antigen and blunt the vaccine-induced immune response. - The investigators said real-world implications for vaccine efficacy remain uncertain because lowered antibody titers do not directly equate to loss of clinical protection; the source did not report downstream clinical endpoints linking reduced titers to infection risk. - Given this interference signal, trial planners will pause combined use in infants and concentrate pivotal approval studies on other populations first, with planned pivotal trials hoped to begin in 2028, the authors noted. - The study did not report specific dosing regimens, sample sizes, statistical significance values, or detailed immunogenicity timepoints in the source article; those methodological details were not provided in the abstract summary covered by the source. - Experts quoted in the report identified other priority use cases for monoclonals: pregnant people, recently hospitalized children as post-discharge protection, and groups where a single-shot several-month cover could be programmatically useful. - Cost and delivery considerations remain relevant: monoclonal doses are relatively expensive, and efforts to reduce price ahead of pivotal trials are underway, according to the article.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/11/19/malaria-monoclonal-antibody-l9ls-vaccine-r21-infant-study-mali/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/19/malaria-monoclonal-antibody-l9ls-vaccine-r21-infant-study-mali/?utm_campaign=rss) [Clinical trials](https://www.statnews.com/topic/clinical-trials/) [aging](https://www.statnews.com/topic/aging/) [research](https://www.statnews.com/topic/research/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT@JPM27](https://www.statnews.com/jpm-conference-stat-events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Trust in Science](https://www.statnews.com/trust-in-science/) * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Madness 2027](https://www.statnews.com/feature/stat-madness/apply/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) China's Biotech Powerhouse 25 We ranked the 25 most valuable publicly traded Chinese drugmakers [ See the list ](https://www.statnews.com/china-biotech-index-powerhouse-25/) [Health](https://www.statnews.com/category/health/) # Study raises doubts about combining vaccine, monoclonal antibody to protect against malaria ## Researchers say monoclonal could still be a useful tool, but pause plans to use it in babies * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/19/malaria-monoclonal-antibody-l9ls-vaccine-r21-infant-study-mali/?utm_campaign=rss) ![A lab worker points to an on screen image of a malaria positive blood sample in South Africa](https://www.statnews.com/wp-content/uploads/2026/11/GettyImages-2279831277-1-645x645.jpg) Malaria killed about 610,00 people in 2024, the majority of them children under 5 years old in sub-Saharan Africa. In the photo above, a lab worker looks at a malaria-positive blood sample in Tintswalo Hospital in Bushbuckridge, South Africa.EMMANUEL CROSET / AFP via Getty Images ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) By [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) Nov. 19, 2026 Europe Correspondent ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) 1. [](https://x.com/DrewQJoseph "X") andrew.joseph@statnews.com Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. [Get email alerts for Andrew JosephSigned up for email alertsRemove email alerts](https://www.statnews.com/2026/11/19/malaria-monoclonal-antibody-l9ls-vaccine-r21-infant-study-mali/?utm_campaign=rss) [Subscribe](https://www.statnews.com/stat-plus/) or [log in](https://www.statnews.com/login/) to STAT+ to unlock email alerts When it comes to preventing malaria, researchers and public health officials have been hopeful about the potential of a monoclonal antibody, one injection of which could provide recipients with several months of protection against the parasite. Such a tool, experts have thought, could give babies a layer of defense even before they start receiving doses of [the malaria vaccines that have rolled out in recent years](https://www.statnews.com/2024/08/01/malaria-vaccines-development-history-40-year-fight-mosquito-borne-disease/). New research detailed Thursday has cast doubt on that strategy. Advertisement Scientists tested the monoclonal, known as L9LS, in infants in Mali, finding that it was 78% effective versus a placebo in providing protection against the malaria parasite over the six-month transmission season, similar to what has been seen in studies of the antibody[ in older kids](https://www.nejm.org/doi/10.1056/NEJMoa2312775) and adults. However, they also reported that it interfered with the immune response the malaria vaccine R21 elicits, resulting in a 20% to 30% drop in antibody levels generated by the immunization, according to an abstract presented at the annual meeting of the American Society of Tropical Medicine and Hygiene. While it’s not clear what the diminished immune responses seen in blood tests would mean for the real-world protection offered by the vaccine, researchers say they’re going to focus on groups other than babies as they plan the pivotal studies that could lead to L9LS being approved, which they hope to start in 2028. Advertisement “We have these other clear use cases, so let’s get those done and get it approved and we can come back and revisit this,” said Robert Seder of the National Institute of Allergy and Infectious Diseases, whose lab helped develop L9LS. Related Story ![](https://www.statnews.com/wp-content/uploads/2024/07/photo-illo-malaria-vaccine-1-768x432.jpg) ### [Behind the malaria vaccines: A 40-year quest against one of humanity’s biggest killers](https://www.statnews.com/2024/08/01/malaria-vaccines-development-history-40-year-fight-mosquito-borne-disease/) There is no panacea against malaria, and various strategies come with advantages and disadvantages that public health officials have to weigh as they think about which approach to prioritize and for whom, particularly given the limited funding for a disease that predominantly affects poor countries. The infection [killed about 610,000 people in 2024](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2025), the majority of them children under 5 years old in sub-Saharan Africa. R21 and RTS,S, [the two malaria vaccines,](https://www.statnews.com/2024/01/22/gsk-malaria-vaccine-mosquirix-rollout-africa/) are seen as major scientific breakthroughs — they are the first vaccines against any parasite — but they require multiple doses to be effective, the first of which comes at 5 months of age. They do, however, provide some level of protection for years. A monoclonal, on the other hand, can provide several months of protection with just one dose, which could be enough to cover recipients for peak transmission periods. (In areas with year-round transmission, deploying antibodies might require two to three doses a year, experts say.) It could offer an alternative to [the current strategy](https://www.smc-alliance.org/seasonal-malaria-chemoprevention-smc) of giving children existing antimalarial treatments every month during high-transmission periods, which is a cheap and effective preventive strategy but that opens the door to adherence challenges. “A monoclonal antibody, with only one shot, provides an efficacy over six months, and those six months correspond to the season of malaria in Sahelian regions,” said Kassoum Kayentao of Mali’s University of Sciences, Techniques, and Technologies of Bamako, one of the experts involved with the new research. “In terms of logistics, in terms of programmatical use, this could be a very good tool.” The constraint with antibodies is that they are comparatively costly, though there are efforts underway to bring down the price of each dose as researchers head to pivotal trials. Advertisement The new study enrolled infants from 1 month to 12 months, gave them either a placebo or the L9LS monoclonal, and then doses of the R21 vaccine. That sequence was what created the issue, researchers said. The malaria vaccines work by training the immune system to recognize a protein on the parasite known as the circumsporozoite protein, or CSP. The monoclonal L9LS also binds to the CSP. That meant that, when the infants who had been given L9LS later received R21, the antibody bound to the vaccine as well, essentially interfering with the full immune response it was meant to trigger, researchers believe. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Daily-Recap-Logo-Black-640x259.png) Newsletter Weekdays ### Sign up for Daily Recap All the health and medical news you need today, in one email Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Experts said there were still key groups of people who could benefit from a monoclonal and who could be the focus of future studies. Among them are pregnant people, as an infection during pregnancy can be dangerous for both parent and baby. Kids who are hospitalized with malaria are another target group. In the months after they’re released from hospital and as they recover from the infection-caused anemia, they are particularly vulnerable to severe outcomes from another malaria case. The current strategy of what’s called post-discharge malaria chemoprevention involves taking available preventive drugs every month, whereas one shot of a monoclonal as they leave the hospital could cover them for months. André-Marie Tchouatieu of the Medicines for Malaria Venture, who was not involved in the study, said that, despite the issue seen with L9LS and the vaccine, it did not limit the potential impact the monoclonal and next-generation versions could have in reducing the burden of malaria broadly. “Definitely there will be a use case,” said Tchouatieu, who this month co-authored [a New England Journal of Medicine review](https://www.nejm.org/doi/full/10.1056/NEJMra2508563) outlining the advantages and challenges of different malaria strategies. “Every tool that can prove efficacy and safety will have a role to play in the whole strategy for malaria elimination.” [global health](https://www.statnews.com/topic/global-health/), [public health](https://www.statnews.com/topic/public-health/), [Vaccines](https://www.statnews.com/topic/vaccines/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) 1. [](https://x.com/DrewQJoseph "X") 2. Europe Correspondent 1. [](https://x.com/DrewQJoseph "X") 2. Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Morning-Rounds-Logo-Black-640x295.png) ### Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2025/09/TheWorkup_Illustration_MollyFerguson_093025-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [I’m a cardiologist. I’m a little puzzled about the blockbuster new study on deprescribing statins](https://www.statnews.com/2026/11/19/deprescribing-statins-study-stream-trial-aha-questions/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/11/peps-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Peptide market poised to explode with new Hims and Noom launches](https://www.statnews.com/2026/11/19/hims-noom-enter-peptide-market-mainstream-products-health-risks/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/11/image-9-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Epic Systems defends competitive practices, promises to let AI access its records](https://www.statnews.com/2026/11/18/epic-defends-competitive-practices-promises-ai-access-to-records/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/11/mahapac-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Before midterm losses, MAHA spent on itself instead of candidates](https://www.statnews.com/2026/11/19/maha-pac-how-it-spent-money-insiders-candidates-nonprofit/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_499879090-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment](https://www.statnews.com/2026/11/19/erasca-kras-targeted-treatment-new-data-pancreatic-cancer/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/10/STATatHLTH_Wordpress_CalendarImage-80x80.jpg) STAT@hlth. A Dose of Reality on EHRs and AI In-person Nov 18 ](https://www.statnews.com/event/stathlth-a-dose-of-reality-on-ehrs-and-ai/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/BTE2027_Wordpress_CalendarImage-80x80.jpg) 2027 Breakthrough Summit East New York City, NY Mar 18 ](https://www.statnews.com/event/2027-stat-breakthrough-summit-east/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2025/09/TheWorkup_Illustration_MollyFerguson_093025-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [I’m a cardiologist. I’m a little puzzled about the blockbuster new study on deprescribing statins](https://www.statnews.com/2026/11/19/deprescribing-statins-study-stream-trial-aha-questions/) 2. ![](https://www.statnews.com/wp-content/uploads/2024/09/GettyImages-1237273640-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA rejects lung cancer treatment ivonescimab from
## Related Clinical Research

- [Leveraging MAHA and Kennedy to Combat Measles Vaccine Hesitancy](https://medichelpline.com/clinical-feed/stat-news-0-opinion-how-kennedy-and-maha-could-help-stop-measles.md)
- [Restoring U.S. Measles Elimination Status: Congressional Actions Needed](https://medichelpline.com/clinical-feed/stat-news-1-opinion-the-u-s-lost-measles-elimination-status-the-next-congress-should-help.md)
- [U.S. POINTER: Structured lifestyle program slows brain aging and cardiometabolic risk over 24 mont](https://medichelpline.com/clinical-feed/medical-news-today-0-combining-physical-mental-and-social-habits-slows-brain-aging-in-2-year-trial.md)
- [Later bedtimes and late eating tied to higher metabolic syndrome risk](https://medichelpline.com/clinical-feed/medical-news-today-0-eating-and-sleeping-later-associated-with-increased-health-risks.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.